SuperworthTarsus Pharmaceuticals profit margin TARS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.
- Net margin, 12 months
- −7.7%
- Operating margin, 12 months
- −8.0%
- Net margin on a year earlier
- +23.5 pts
- Peer median
- 22.9%
Over the twelve months to Jun 30, 2026, Tarsus Pharmaceuticals kept −7.7% of its revenue as net profit, with an operating margin of −8.0% and a gross margin of 93.3%.
Five years earlier its net margin was −8.8%.
The median for 10 biotech stocks of a similar size is 22.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −14.7% | −15.7% | 93.2% |
| FY2024 | −63.2% | −65.9% | 93.0% |
| FY2023 | n/a | n/a | 90.9% |
| FY2022 | n/a | n/a | 96.3% |
| FY2021 | n/a | n/a | n/a |
| FY2020 | n/a | n/a | n/a |
| FY2019 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −7.7% | +23.5 pts | −8.0% | |
| Q1 FY26 | −9.0% | +35.9 pts | −9.5% | |
| Q4 FY25 | −14.7% | +48.4 pts | −15.7% | |
| Q3 FY25 | −22.2% | n/a | −23.9% | |
| Q2 FY25 | −31.1% | n/a | −33.2% | |
| Q1 FY25 | −44.9% | n/a | −46.7% | |
| Q4 FY24 | −63.2% | n/a | −65.9% | |
| Q3 FY24 | n/a | n/a | n/a | |
| Q2 FY24 | n/a | n/a | n/a | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | n/a | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| TARSTarsus Pharmaceuticals | −7.7% |
| ADMAAdma Biologics | 33.0% |
| VCELVericel | 7.9% |
| KRYSKrystal Biotech | 54.8% |
| RGENRepligen | 5.3% |
| MGTXMeiraGTx | 19.9% |
| TECHBIO-TECHNE | 15.0% |
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| INCYIncyte | 27.7% |
| Peer median | 22.9% |
Where Tarsus Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Tarsus Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.